- Home
- CLRB vs KZR Comparison
CLRB vs KZR Comparison
Compare CLRB & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- KZR
- Stock Information
- Founded
- CLRB 2002
- KZR 2015
- Country
- CLRB United States
- KZR United States
- Employees
- CLRB N/A
- KZR N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- KZR Health Care
- Exchange
- CLRB Nasdaq
- KZR Nasdaq
- Market Cap
- CLRB 76.0M
- KZR 65.3M
- IPO Year
- CLRB N/A
- KZR 2018
- Fundamental
- Price
- CLRB $1.86
- KZR $7.53
- Analyst Decision
- CLRB Strong Buy
- KZR Hold
- Analyst Count
- CLRB 2
- KZR 2
- Target Price
- CLRB $21.00
- KZR $11.00
- AVG Volume (30 Days)
- CLRB 289.0K
- KZR 61.7K
- Earning Date
- CLRB 11-18-2024
- KZR 11-12-2024
- Dividend Yield
- CLRB N/A
- KZR N/A
- EPS Growth
- CLRB N/A
- KZR N/A
- EPS
- CLRB N/A
- KZR N/A
- Revenue
- CLRB N/A
- KZR N/A
- Revenue This Year
- CLRB N/A
- KZR N/A
- Revenue Next Year
- CLRB N/A
- KZR $66.68
- P/E Ratio
- CLRB N/A
- KZR N/A
- Revenue Growth
- CLRB N/A
- KZR N/A
- 52 Week Low
- CLRB $1.82
- KZR $5.20
- 52 Week High
- CLRB $4.45
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- CLRB 30.70
- KZR 49.59
- Support Level
- CLRB $1.97
- KZR $7.27
- Resistance Level
- CLRB $2.18
- KZR $7.50
- Average True Range (ATR)
- CLRB 0.10
- KZR 0.48
- MACD
- CLRB -0.01
- KZR -0.08
- Stochastic Oscillator
- CLRB 8.11
- KZR 40.00
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.